ARTICLE | Company News
bioMerieux, ProteoSys deal
October 6, 2008 7:00 AM UTC
ProteoSys granted bioMerieux semi-exclusive, worldwide rights to IP covering the biomarker annexin A3 (ANXA3) to develop a diagnostic for prostate cancer. ProteoSys will receive an undisclosed upfron...